Prescient Therapeutics Ltd. announced the appointment of the H. Lee Moffitt Cancer Center's Professor Jeffrey Lancet MD to PTX's Scientific Advisory Board (SAB). Professor Lancet is a medical oncologist whose work involves the development and implementation of clinical trials using small molecule inhibitors in acute leukaemias. This is of particular interest to PTX ahead of an upcoming clinical trial in Acute Myeloid Leukaemia (AML) in early 2016.

Professor Lancet was an investigator on PTX's earlier Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Center in 32 patients with advanced haematologic malignancies.